FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
Sep 11, 2026
MIAMI - Sept. 11, 2026 - PRLog -- NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) ("NRx Pharmaceuticals," "NRx" or the "Company"), $NRXP a clinical-stage biopharmaceutical company, announced that its subsidiary, HOPE Therapeutics, Inc. ("HOPE"), is positioned to become the first Interventional Psychiatry organization to deploy Zeta Surgical's newly FDA-cleared Zeta TMS Robotic System, with clinical staff now undergoing training ahead of deployment in Florida.
This latest development adds an important new dimension to the increasingly broad NRx story.
Rather than focusing solely on pharmaceutical development, NRx is building an integrated neuropsychiatric platform combining advanced TMS technology, clinical treatment infrastructure, pharmaceutical development and emerging precision-treatment capabilities. The planned deployment of Zeta Surgical's robotic system represents another step in that strategy and comes at a particularly interesting time for investors.
NRx CEO Jonathan Javitt, M.D., M.P.H., is also taking the company's story directly to the investment community this week, including a scheduled appearance at the Cantor Global Healthcare Conference today, September 11, followed by the H.C. Wainwright 28th Annual Global Investment Conference on September 14.
For investors following N A S D A Q: NRXP, the timing is notable.
The company is approaching a potentially important period with FDA regulatory progress, commercial manufacturing underway, HOPE Therapeutics expansion, advanced TMS deployment, NRX-101 development and a potential DARPA-funded Phase 2/3 program all moving forward.
HOPE Therapeutics and Zeta Surgical: From Technology to Clinical Deployment
Today's announcement is particularly significant because it moves the Zeta Surgical relationship another step toward real-world implementation.
HOPE is preparing its clinical staff for deployment of the newly FDA-cleared Zeta TMS Robotic System in Florida. The system is designed to bring robotic precision and advanced image guidance to TMS treatment, potentially improving the ability of clinicians to consistently target specific areas of the brain.
For NRx, this fits directly into HOPE Therapeutics' broader strategy of developing an advanced Interventional Psychiatry platform.
HOPE has already expanded its Florida clinical footprint and previously became the first commercial site in the United States to deploy Zeta Surgical's FDA-cleared TMS Navigation System. The new robotic system potentially represents another technological step forward.
Why investors may find this important:
- HOPE is moving toward deployment of newly FDA-cleared robotic TMS technology.
- Clinical personnel are already being trained ahead of Florida deployment.
- The technology complements NRx's broader TMS and neuropsychiatric strategy.
- HOPE provides NRx with an operating clinical platform rather than relying solely on pipeline development.
- The technology could become increasingly relevant to the company's NRX-101/TMS development strategy.
FDA Progress Remains the Major Near-Term Catalyst
While today's HOPE announcement adds significant strategic interest, the company's preservative-free ketamine program remains one of the most important potential near-term catalysts.
On August 7, NRx announced that the FDA had completed its first-cycle review of the company's ANDA for preservative-free ketamine without identifying drug-related major deficiencies.
The remaining FDA question concerns the vial's luer-lock component. NRx has emphasized that the remaining issue is related to the container closure system rather than the ketamine product itself, its ingredients, labeling, Chemistry, Manufacturing and Controls, or clinical data.
The company submitted the requested manufacturer attestation.
Most importantly for investors, NRx has stated that no new clinical, safety or efficacy data are required for ANDA approval.
The company continues to target potential approval and commercialization during 2026.
Commercial Manufacturing Is Already Underway
$NRXP has been preparing for a potential launch before receiving final FDA approval.
The company has initiated commercial-scale manufacturing and is building approximately 5 million doses of launch inventory, with anticipated post-launch manufacturing capacity of approximately 1 million doses per month.
NRx has also established a commercial launch team and appointed Glenn Tyson as its first Chief Commercial Officer.
This means the company is attempting to position itself to move quickly from regulatory approval to commercial execution.
For a small-cap biotechnology company, that distinction is important.
The story is increasingly becoming about launch readiness, not simply laboratory development.
NRX-101 Could Provide a Second Major Growth Opportunity
The other major component of the NRx pipeline is NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone.
NRX-101 has received FDA Breakthrough Therapy Designation for suicidal bipolar depression, and NRx is developing the program in conjunction with advanced TMS approaches.
In June, the FDA granted an Expanded Access Protocol for D-cycloserine-based NRX-101 as an augmentation to accelerated TMS for depression.
NRx subsequently announced that its defense subsidiary had been selected by DARPA as prime contractor for the SPARC-TMS program, an FDA-approved Phase 2/3 trial combining NRX-101 with robotic TMS.
The potential non-dilutive funding is expected to exceed $11.5 million, subject to completion of contracting.
The combination of NRX-101 and robotic TMS is particularly interesting in light of today's HOPE Therapeutics announcement, because the company is simultaneously developing the therapeutic program while building access to advanced TMS technology within its clinical platform.
A Stronger Balance Sheet Provides Additional Runway
NRx also significantly strengthened its financial position during 2026.
The company completed an institutionally supported public offering generating approximately $22.3 million in gross proceeds, including full exercise of the underwriters' option.
As of June 30, NRx reported approximately $26.7 million in cash and cash equivalents, compared with $7.8 million at year-end 2025.
Management believes its existing cash resources, anticipated clinic revenue and potential ATM utilization provide at least one year of operating runway.
That additional financial flexibility could be important as NRx moves simultaneously toward potential commercialization and continued clinical development.
A Rapidly Expanding Investor Catalyst List
NRXP investors now have several potential catalysts to monitor:
- Deployment of the FDA-cleared Zeta TMS Robotic System at HOPE Therapeutics
- FDA resolution of the remaining preservative-free ketamine certification
- Potential 2026 commercialization
- Five-million-dose launch inventory
- Manufacturing scale-up toward approximately one million doses monthly
- DARPA contracting and potential $11.5 million-plus non-dilutive funding
- NRX-101 clinical development
- Progress toward the NRX-100 NDA
- Continued HOPE Therapeutics expansion
- Additional investor presentations and institutional awareness
And with management meeting investors at major healthcare conferences this week, the company has a timely opportunity to explain how these initiatives fit together.
Investor Perspective
NRx Pharmaceuticals remains a speculative small-cap biotechnology investment, and FDA decisions, clinical outcomes, financing requirements, manufacturing execution and commercial adoption all carry meaningful risk.
However, the company's story has expanded considerably.
Today's HOPE Therapeutics announcement is another example of that evolution.
NRx is not simply developing therapies in isolation. It is attempting to build an integrated neuropsychiatric ecosystem involving pharmaceutical development, advanced TMS, robotic treatment technology, clinical infrastructure and government-supported research.
The planned deployment of Zeta Surgical's newly FDA-cleared Zeta TMS Robotic System—combined with clinical staff already training for deployment in Florida—gives investors another tangible milestone to watch.
At the same time, the preservative-free ketamine program is approaching a potentially decisive FDA milestone, commercial manufacturing is underway, millions of doses are being prepared for a potential launch, and NRX-101 has gained significant momentum through its FDA designations and potential DARPA-supported clinical program.
That convergence is what makes the current NRXP story particularly compelling.
With CEO Jonathan Javitt appearing before healthcare investors today at the Cantor Global Healthcare Conference, followed by another major investor presentation on September 14, the market will have an opportunity to hear directly from management at a time when several pieces of the NRx strategy are beginning to come together.
For more information on $NRXP visit: https://www.nrxpharma.com/ and https://compasslivemedia.com/case-study/nrx-pharmaceuticals/
Media Contact
Company Name: NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)
Contact Person: Brian Korb, Managing Partner, astr partners
Email: [email protected]
Phone: (917) 653-5122
Country: United States
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Photos: (Click photo to enlarge)
Source: CorporateAds
Read Full Story - FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP) | More news from this source
Press release distribution by PRLog
FTC's costly crackdown on conglomerates generates little return
The Fair Trade Commission’s (FTC) increasingly aggressive crackdown on major conglomerates is generating a costly cycle with little tangible return, as the watchdog has been forced to refund billions of won in fines overturned by courts. The watchdog has returned nearly 290 billion won ($216.7 million) to companies since 2022 after administrative court rulings overturned its sanctions. The figures raise questions about whether the regulator’s tougher enforcement produces lasting results or simply creates more legal and financial burdens for both businesses and taxpayers. The latest figures offer little reassurance. For the first nine months combined this year, the FTC returned 23 billion won in fines and associated payments, with 99.7 percent of the amount attributable to sanctions overturned in whole or in part through administrative litigation, according to data submitted to Rep. Choi Eun-seok of the main opposition People Power Party. But the regulator is moving in the opposite direction. Since President Lee Jae Myung took office last year, the government has pushed to strengthen
The AI promise was automation. The reality? Managing digital workers
When artificial intelligence agents first arrived, they came with a tantalising promise: autonomous “digital workers” that would finally free humans from corporate drudgery. As businesses across Asia are discovering, however, the reality is quite the opposite – more work, new friction and a whole new layer of management. When Xiao Mengjie, an AI product marketing manager at a Big Tech firm in Shanghai, recently assigned two AI agents what she described as a simple task, she expected efficiency....
[Reporter's Notebook] FTC's costly crackdown on conglomerates generates little return
The Fair Trade Commission’s (FTC) increasingly aggressive crackdown on major conglomerates is generating a costly cycle with little tangible return, as the watchdog has been forced to refund billions of won in fines overturned by courts. The watchdog has returned nearly 290 billion won ($216.7 million) to companies since 2022 after administrative court rulings overturned its sanctions. The figures raise questions about whether the regulator’s tougher enforcement produces lasting results or simply creates more legal and financial burdens for both businesses and taxpayers. The latest figures offer little reassurance. For the first nine months combined this year, the FTC returned 23 billion won in fines and associated payments, with 99.7 percent of the amount attributable to sanctions overturned in whole or in part through administrative litigation, according to data submitted to Rep. Choi Eun-seok of the main opposition People Power Party. But the regulator is moving in the opposite direction. Since President Lee Jae Myung took office last year, the government has pushed to strengthen
Street Fighter: a fighting game movie that fans must see
MANILA, Philippines – For nearly four decades since it started out as a small arcade game and eventually turned into the fighting game franchise powerhouse it is today, Capcom’s Street Fighter series is as universally recognizable as every iconic property and brand known in popular culture. The series has undergone several evolutionary leaps since it
Apple’s new HomePod mini 2 speakers feature Sound Glow and will eventually support Siri AI
It’s been six years since the first HomePod mini, so now we are getting a much-needed update to keep it fresh.
Meta wants to put more AI technology on our faces
At Meta Connect 2026, Meta unveiled its latest AI glasses, shared how they’re bringing the Muse personal AI agent to glasses, and introduced the all-new Meta VR Glasses.
Casetify gives Hello Kitty a very Y2K makeover with its latest collection
Leopard prints, hot pink and sticker-covered cases bring early-2000s visuals to iPhones and other accessories.
Only 17% of Philippine businesses have a roadmap to scale AI
Only 17% of businesses in the Philippines have a roadmap for scaling artificial intelligence (AI), highlighting a gap between growing adoption of the technology and companies’ ability to integrate it more deeply into their operations. The finding comes from Unlocking the Philippines’ AI Potential 2026, a report commissioned by Amazon Web Services (AWS) and conducted
Securing equipment emerges as new variable for Korea's chip expansion plans
Securing equipment for manufacturing advanced memory chips is emerging as a new variable in Korea's plans to expand semiconductor production capacity through large-scale industrial clusters, after ASML, the dominant supplier of advanced chipmaking equipment, warned that its current production plans may not be sufficient to meet demand in 2027 and 2028. During its earnings call Wednesday, ASML CEO Christophe Fouquet said the company's plans to increase its production capacity for advanced chipmaking equipment by 30 percent in 2027 and another 30 percent in 2028 would likely not be enough to meet customer demand. “Last quarter, we talked about 30 percent more capacity next year, and also the aspiration to have another 30 percent increase in 2028,” Fouquet said. “But to be honest, it's becoming very clear that 30 percent in 2027, 30 percent in 2028 will not allow us to meet our customer demand.” According to the company, the planned capacity increases cover both low-numerical-aperture extreme ultraviolet (low-NA EUV) lithography equipment and deep ultraviolet (DUV) immersion system
Musinsa teams up with Japan's ZOZOTOWN for 1st Korean pop-up
Fashion platform Musinsa has teamed up with ZOZOTOWN, one of Japan's leading online fashion retailers, to open a pop-up store in Seongsu-dong, Seoul, a popular destination for young consumers. Musinsa opened the doors to ZOZOTOWN in Musinsa, the Japanese platform’s first official pop-up store in Korea, to the media on Friday. The pop-up will run through Oct. 31, while an accompanying online promotion will continue until Nov. 16. Launched in 2004, ZOZOTOWN features more than 11,000 brands and serving over 13 million customers annually. Fifteen Japanese fashion brands available on the platform, including Snidel and Grancy, are participating in the event. The pop-up’s concept, ZOZO is Coming to Town, draws inspiration from Korean streets. Crosswalks, road markings and oversized three-dimensional typography have been incorporated into the space to create the impression of an intersection where Korean and Japanese fashion meet. The pop-up follows the signing of a memorandum of understanding between the two platforms in December 2024 to establish a strategic partnership. In November last y
China’s proposed AI tech export bans may create short-term costs, long-term gains: analysts
China’s proposed export bans and controls of artificial intelligence technologies aim to tighten Beijing’s grip in the strategically vital sector, casting a cloud over the commercial prospects of domestic model developers in the global AI race, analysts say. The new measures come as concerns mount globally over the risks of advanced AI systems, following a string of recent cyberattacks, while also underscoring AI’s growing national security importance for both Beijing and Washington. Zhang Yi,...
EA producer confirms the return of Wing Commander
MANILA, Philippines – A panel at the Portland Retro Gaming Expo on game preservation revealed that the master tapes containing high quality source video for Wing Commander III were located. The contents of these tapes will now undergo restoration and preparation is at work for a new release of the game, tentatively called Wing Commander
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.